ProVise Management Group’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-4,634
| Closed | -$458K | – | 292 |
|
|
2024
Q3 | $458K | Buy |
4,634
+301
| +7% | +$29.7K | 0.04% | 202 |
|
|
2024
Q2 | $402K | Hold |
4,333
| – | – | 0.03% | 208 |
|
|
2024
Q1 | $411K | Buy |
4,333
+731
| +20% | +$69.4K | 0.04% | 207 |
|
|
2023
Q4 | $322K | Sell |
3,602
-449
| -11% | -$40.1K | 0.03% | 276 |
|
|
2023
Q3 | $296K | Hold |
4,051
| – | – | 0.03% | 275 |
|
|
2023
Q2 | $337K | Hold |
4,051
| – | – | 0.03% | 270 |
|
|
2023
Q1 | $309K | Hold |
4,051
| – | – | 0.03% | 280 |
|
|
2022
Q4 | $336K | Hold |
4,051
| – | – | 0.03% | 243 |
|
|
2022
Q3 | $321K | Hold |
4,051
| – | – | 0.04% | 243 |
|
|
2022
Q2 | $301K | Buy |
4,051
+1,000
| +33% | +$74.3K | 0.03% | 256 |
|
|
2022
Q1 | $274K | Sell |
3,051
-500
| -14% | -$44.9K | 0.03% | 300 |
|
|
2021
Q4 | $398K | Hold |
3,551
| – | – | 0.04% | 262 |
|
|
2021
Q3 | $446K | Hold |
3,551
| – | – | 0.04% | 237 |
|
|
2021
Q2 | $481K | Sell |
3,551
-746
| -17% | -$101K | 0.05% | 234 |
|
|
2021
Q1 | $583K | Buy |
4,297
+449
| +12% | +$60.9K | 0.06% | 207 |
|
|
2020
Q4 | $542K | Sell |
3,848
-397
| -9% | -$55.9K | 0.06% | 202 |
|
|
2020
Q3 | $473K | Buy |
4,245
+873
| +26% | +$97.3K | 0.06% | 198 |
|
|
2020
Q2 | $377K | Buy |
3,372
+430
| +15% | +$48.1K | 0.05% | 206 |
|
|
2020
Q1 | $228K | Buy |
+2,942
| New | +$228K | 0.04% | 233 |
|